Clinical efficacy of blood purification using a polymethylmethacrylate hemofilter for the treatment of severe acute pancreatitis

Kiyohiko Kinjoh¹, Ryoji Nagamura², Yutaka Sakuda³, Shoki Yamauchi³, Hideta Takushi³, Tadashi Iraha⁴, Koji Idomari⁴

¹Division of Blood Purification Therapy, ²Department of Gastroenterology, ³Intensive Care Unit, and ⁴Department of Emergency Medicine, Okinawa Kyodo Hospital, Okinawa, Japan

Background: Severe acute pancreatitis (SAP) is a systemic inflammatory disease, and it can often complicate into acute kidney injury (AKI) and acute lung injury/acute respiratory distress syndrome (ALI/ARDS). This study aimed to evaluate the clinical effectiveness of blood purification using a polymethylmethacrylate (PMMA) hemofilter.

Methods: We retrospectively examined 54 patients, who were diagnosed with SAP according to the Japanese criteria from January 2011 to December 2019.

Results: Of a total of 54 SAP patients, 26 patients progressively developed AKI and required continuous hemodialysis with a PMMA membrane hemofilter (PMMA-CHD). Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score were significantly higher in patients requiring PMMA-CHD than in patients not requiring hemodialysis. The lung injury scores were also significantly higher in patients requiring PMMA-CHD. Of the 26 patients, 16 patients developed ALI/ARDS and required mechanical ventilation. A total of seven patients developed severe ALI/ARDS and received additional intermittent hemodiafiltration using a PMMA hemofilter (PMMA-HDF). Although the length of intensive care unit stay was significantly longer in patients with severe ALI/ARDS, blood purification therapy was discontinued in all the patients. The survival rates at the time of discharge were 92.3% and 92.9% in patients with and without PMMA-CHD, respectively. These real mortality ratios were obviously lower than the estimated mortality ratios predicted by APACHE II scores.

Conclusions: These findings suggest that the blood purification using a PMMA hemofilter would be effective for the treatment of AKI and ALI/ARDS in SAP patients.

Key Words: acute kidney injury; acute lung injury; acute respiratory distress syndrome; continuous renal replacement therapy; pancreatitis; polymethylmethacrylate hemofilter

INTRODUCTION

Acute pancreatitis (AP) is a common gastrointestinal disease, and the majority of AP patients usually experience a mild course of disease. However, in approximately 20% of AP patients, damage to the tissue around the pancreatitis could worsen further, resulting in deterioration with multiple organ failure (MOF) and subsequent diagnosis of severe AP (SAP), particu-
larly hampering the kidney and pulmonary functions [1,2]. If acute kidney injury (AKI) develops, the mortality of SAP patients increases to between 20% and 80% [2,3]. More recent publications have reported a decrease in the mortality of AP patients with AKI over the past decade; however, AKI is still independently associated with higher mortality [4]. As in other critically ill patients with AKI, renal replacement therapy is indicated as a treatment method in such cases [5]. Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is also known as a major complication of SAP and has been reported to be associated with an increased mortality of up to 50% [6].

Although blood purification therapy is not a standard therapy for SAP, continuous blood purification therapy using a polymethylmethacrylate (PMMA) hemofilter is used as a potential treatment method for SAP in Japan. A hemofilter made from a PMMA hollow-fiber membrane is reportedly capable of efficiently removing the proinflammatory mediators from the blood through adsorption [7,8]. It shows a positive effect on patients with systemic inflammatory response syndrome (SIRS), such as septic shock, ARDS, and SAP [9-11]. This study aimed to present our clinical experience of the last 9 years of managing SAP patients requiring continuous hemodialysis with a PMMA membrane hemofilter (PMMA-CHD) and to evaluate the improvement in organ failures of AKI and/or ALI/ARDS and treatment outcomes.

MATERIALS AND METHODS

Study Design, Patients, and Treatments

This study was approved by the Ethical Committee of Okinawa Kyodo Hospital. Informed consent was obtained from all patients. We retrospectively reviewed a total of 54 patients who were diagnosed with SAP according to the Japanese severity criteria for AP of the Japanese Ministry of Health, Labour, and Welfare [12] and were admitted to the intensive care unit (ICU) between January 1, 2011, and December 31, 2019. According to the Japanese criteria, SAP was determined as grade 2 or 3 of pancreatic tissue involvement evaluated by contrast-enhanced computed tomography (CT) with optional evaluation by prognostic factors [12]. Initially, for these patients were treated with conventional therapy, including massive infusion and administration of diuretics, antibiotics, and multi-enzymatic protease inhibitors, according to Japanese guidelines for the management of SAP [13]. Nevertheless, when patients had anuria or oliguria with <200 ml urine output during the initial 8–12 hours of ICU stay, they were treated with PMMA-CHD, as described below. During treatment with PMMA-CHD, diuretic administration was continued. If patients developed ALI/ARDS with further systemic deterioration, high-flow-volume hemodiafiltration (HDF) using a 2.1-m² PMMA hemofilter was intermittently used between sessions of PMMA-CHD. Blood purification therapies were discontinued when both AKI and ALI/ARDS improved, defined as improved oliguria (urine output >600 ml/day) and a PaO₂/FiO₂ ratio of >400 or extubation in patients in the ventilation group.

Blood Purification Therapy

A double-lumen catheter was inserted in the cervical or femoral vein for blood access. ACH-Σ (Asahi-Kasei, Tokyo, Japan) was used for continuous hemodialysis. Continuous hemodialysis was initiated using a 1.3-m² PMMA hemofilter (Hemofeel CH-1.3W; Toray, Tokyo, Japan). The blood flow rate was set at 80 ml/min, and the flow rate of dialysate was set at 600 ml/hr. The hemofilter was exchanged every 24–48 hours. Nafamostat mesilate (Torii Pharmaceutical, Tokyo, Japan), a synthetic serine protease inhibitor, was used as an anticoagulant. From the second or third day of ICU stay, a large-sized (1.8 m²) PMMA hemofilter (Hemofeel CH-1.8W, Toray) was used. For further deteriorated patients, intermittent PMMA-HDF was used for 6 hours between interrupted PMMA-CHD sessions, according to the procedure described by Nishida et al. [14], with some modifications as follows: a 2.1-m² hemofilter (NF-2.1H, Toray) was used. The blood flow rate was set at 80–120 ml/min, the flow of dialysate was set at 300 ml/min, and the filtration rate was set at 1,000 ml/hr using a HDF equipment, NDF-21 (Nipro,
Evaluation of the Severity of Patient Conditions

Acute Physiology and Chronic Health Evaluation (APACHE) II scores were used to evaluate the severity of patients before initiating the blood purification therapy in the ICU [15]. Sequential Organ Failure Assessment (SOFA) scores were used to assess the severity of organ failures during the clinical course in the ICU [16]. The pancreas and/or surrounding tissues were classified based on the Balthazar CT severity index (CTSI) [17].

Statistical Analysis

Data are presented as mean±standard deviation. Categorical variables were analyzed using the Fisher’s exact test. The Wilcoxon rank-sum test was used for two-group comparison. Statistical software (JMP ver. 14; SAS Institute, Cary, NC, USA) was used for these analyses. Significant differences between groups were decided at P<0.05.

RESULTS

Among 54 SAP patients, 26 patients progressively developed anuria or oliguria during the initial 8–12 hours of ICU stay and were treated with PMMA-CHD (PMMA-CHD group) (Figure 2). The baseline characteristics of all 54 patients are summarized in Table 1. No significant differences were noted in the age, sex, body mass index, etiology, Japanese grade evaluated with contrast-enhanced CT, and Balthazar CTSI between the PMMA-CHD and non-hemodialysis groups.

The serum amylase levels were remarkably high in both the groups. AKI was significantly more severe in patients in the PMMA-CHD group than in those in the non-hemodialysis group, as per the KDIGO stage at admission. The APACHE II and SOFA scores were also significantly higher in patients requiring PMMA-CHD (Table 1). The LIS of the patients in the PMMA-CHD group was significantly higher than that of pa-
Patients in the non-hemodialysis group. The final survival ratio showed no significant difference between these two groups.

Among 26 patients who required PMMA-CHD, 16 patients developed ALI/ARDS and consequently required mechanical ventilation with significant differences (Table 2). A total of 12 patients were intubated. Two patients required mechanical ventilation in the non-hemodialysis group (n=28). Patients in the ventilation group showed severe deteriorated lung and tissue involvement around the pancreas with significant high LIS and Balthazar CTSI (Table 2). The duration of hemodialysis therapy was significantly longer in the ventilation group than in the non-ventilation group; moreover, the length of ICU stay was longer in this group. However, there was no significant difference in the survival ratio between these two groups (Table 2).

Among the 16 ventilated patients, 7 showed further deteriorated lung and tissue involvement around the pancreas with significant high LIS and Balthazar CTSI. A total of 28 patients were admitted to our ICU. Among them, 26 patients required continuous hemodialysis with a polymethylmethacrylate membrane hemofilter (PMMA-CHD) during their ICU stay and 16 patients required ventilation for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS).

Table 1. Profiles of patients who required PMMA-CHD

| Variable                                | Without hemodialysis | PMMA-CHD          | P-value |
|-----------------------------------------|----------------------|-------------------|---------|
| Number of patients                      | 28                   | 26                |         |
| Age (yr)                                | 50.5±17.0            | 52.1±17.4         | 0.890   |
| Sex (male:female)                       | 19:9                 | 16:10             | 0.777   |
| Body mass index (kg/m²)                 | 23.7±4.4             | 25.0±3.3          | 0.250   |
| Basic disorder                          |                      |                   |         |
| Alcohol abuse                           | 18                   | 17                |         |
| Cholelithiasis                          | 6                    | 3                 |         |
| Diabetic hyperglycemia                  | 1                    | 1                 |         |
| Hyperlipidemia                          | 1                    | 0                 |         |
| Pancreatic cancer                       | 0                    | 1                 |         |
| Unidentified                            | 2                    | 3                 |         |
| Serum amylase (IU/L)                    | 1,510±1,711          | 1,463±1,466       | 0.917   |
| APACHE II score                         | 7.0±3.8              | 13.2±6.6          | <0.001  |
| SOFA score                              | 2.7±2.6              | 4.9±2.7           | 0.002²  |
| Balthazar CTSI score                    | 5.8±1.3              | 6.7±1.6           | 0.056   |
| Japanese enhanced CT grade              | 2.7±0.5              | 2.5±0.5           | 0.110   |
| KDIGO stage                             | 0.5±0.6              | 2.3±0.7           | <0.001  |
| Lung injury score                       | 1.2±1.4              | 4.3±2.6           | <0.001  |
| Artificial ventilation                  | 2 (7.1)              | 16 (61.5)         | <0.001  |
| Hours of starting CHD²                   | 24.6±18.2            |                   |         |
| Total days of blood purification        | 5.0±4.0              |                   |         |
| Days of ICU care                        | 4.2±3.3              | 9.2±6.1           | <0.001  |
| %Mortality predicted by APACHE II score | 9.4±6.7              | 27.9±31.7         | 0.001²  |
| 28-Day survival (%mortality)            | 27 (3.6)             | 26 (0)            | 0.491   |
| Total hospitalization days              | 15.6±6.8             | 30.2±22.1         | 0.491   |
| Survivor at discharge (%mortality)      | 26 (7.1)             | 24 (7.7)          | 0.723   |

Values are presented as mean±standard deviation unless otherwise indicated.

PMMA-CHD: continuous hemodialysis with a polymethylmethacrylate membrane hemofilter; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CTSI: computed tomography (CT) severity index; KDIGO: Kidney Disease: Improving Global Outcome; ICU: intensive care unit.

²Statistically significant, P<0.05; ³Hours to initiation of PMMA-CHD from ICU admission.
Table 2. Profile and data of patients requiring PMMA-CHD with/without artificial ventilation

| Variable                        | Non-ventilation | Ventilation | P-value |
|---------------------------------|-----------------|-------------|---------|
| Number of patients              | 10              | 16          | -       |
| Age (yr)                        | 43.0±17.8       | 51.5±17.8   | 0.463   |
| Sex (male:female)               | 6:4             | 10:6        | 0.747   |
| Body mass index (kg/m²)         | 24.0±3.4        | 25.6±3.2    | 0.126   |
| Serum amylase (IU/L)            | 1,187±1,426     | 1,635±1,510 | 0.363   |
| APACHE II score                 | 11.7±7.0        | 15.0±6.4    | 0.140   |
| SOFA score                      | 4.7±3.0         | 5.3±2.3     | 0.509   |
| Balthazar CTSI score            | 6.2±1.1         | 7.5±1.6     | 0.029*  |
| Japanese enhanced CT grade      | 2.5±0.5         | 2.4±0.5     | 0.760   |
| KDIGO stage                     | 2.3±0.9         | 2.3±0.7     | 0.906   |
| Lung injury score               | 2.4±1.7         | 6.6±1.6     | <0.001* |
| Day of artificial ventilation   | -               | 7.2±4.4     |         |
| Total days of blood purification| 2.2±1.4         | 6.7±4.3     | <0.001* |
| Day of ICU care                 | 6.4±4.3         | 12.5±6.7    | 0.007   |
| %Mortality predicted by APACHE II score | 28.9±33.4     | 27.4±31.8   | 0.771   |
| 28-Day survival (%mortality)    | 10 (0)          | 16 (0)      | -       |
| Total hospitalization days      | 24.4±17.3       | 33.8±25.0   | 0.342   |
| Survivor at discharge (%mortality) | 9 (10.0)      | 15 (6.2)    | 1.000   |

Values are presented as mean±standard deviation unless otherwise indicated.

PMMA-CHD: continuous hemodialysis with a polymethylmethacrylate membrane hemofilter; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CTSI: computed tomography (CT) severity index; KDIGO: Kidney Disease: Improving Global Outcome; ICU: intensive care unit.

*rStatistically significant, P<0.05.

ration of their respiratory condition with sepsis (n=2), necrotizing pancreatitis (n=2), cardiac failure (n=2), or systemic infection with herpes simplex virus (n=1). High-flow-volume HDF was performed on these seven patients using a 2.1-m² PMMA hemofilter intermittently between PMMA-CHD (Table 3). In these patients, the LIS was significantly increased with significantly longer periods for blood purification. However, these seven patients recovered fully and survived, as shown in Table 3.

All the 26 patients in the PMMA-CHD group discontinued blood purification therapy after improvement in APACHE II score, SOFA score, KDIGO stage, and LIS (Figure 3). On day 28, all the 26 patients with PMMA-CHD survived, and 24 patients (92.3%) recovered fully and were discharged from the hospital (Table 1). In the non-hemodialysis group, 26 patients (92.9%) survived and were discharged from the hospital; however, two patients in this group died from severe alcoholic liver failure after recovering from SAP on days 26 and 29. In the PMMA-CHD group, two patients died; one patient in the non-ventilation group died of pancreatic cancer on day 59 and one patient in the ventilation group died of ICU-acquired weakness with severe pneumothorax from unidentified causes on day 58. No significant differences were noted in the final survival rate between the PMMA-CHD and non-hemodialysis groups and the ventilation and non-ventilation groups, as described above. Compared with the high estimated mortality ratio predicted using APACHE II score, the observed mortality in our study was obviously low, and the real mortality ratio did not increase in patients requiring blood purification (Table 1). Although the predicted mortality was significantly higher in the PMMA-CHD group than in the non-hemodialysis group, there were no significant differences in the observed mortality rate between these two groups (Table 1). The calculated standardized mortality ratio (SMR) was 0.76 in the non-hemodialysis group and 0.28 in the PMMA-CHD group. Thus, the SMR was remarkably lower than the expected ratio, especially in the blood purification group of PMMA-CHD.

**DISCUSSION**

Despite significant progress in the treatment and management, SAP remains a severe medical condition associated with MOF and poor clinical outcomes. SAP can often progress into AKI [3], wherein immune dysregulation, particularly overexpression of proinflammatory cytokines, is reportedly
associated with organ failure [20]. Notably, the interleukin (IL)-6 and tumor necrosis factor (TNF)-α levels were shown to be associated with mortality in this disease [21]. Based on these findings, the use of blood purification therapies has been attempted to decrease the serum cytokine levels [22]. A PMMA hemofilter has been reported to reduce the cytokine levels in vivo and ex vivo [7,11].

It has been reported that continuous hemofiltration (CHF) ranging from 2,000 to 2,500 ml/hr using polysulfone filters reduced the TNF-α, IL-4, and IL-6 levels in patients with SAP complicated with pulmonary failure [22]. Moreover, PMMA hemofilters reportedly have a unique characteristic to adsorb proinflammatory cytokines, thereby yielding good clinical efficacy for patients with SAP [11]. Rasch et al. [23] reported that cytokine adsorption by an AN60 hemofilter was effective for stabilizing hemodynamics in SAP patients, with a decrease in the level of IL-6 or other inflammation markers. Comparing the 28-day survival rate in patients requiring continuous renal replacement therapy, acute blood purification therapy using an AN69 hemofilter showed better survival rates than that using a PMMA hemofilter [20]. Thus, blood purification therapy could be a useful option for the treatment of SAP patients. On the other hand, there was a report stating that the mortality of SAP was significantly higher in patients requiring blood purification therapy as compared to those without blood purification therapy [21]. Thus, blood purification therapy is still considered as a controversial procedure. However, in this study, SAP was improved by the use of PMMA-CHD (Figure 3). Intermittent PMMA-HDF during PMMA-CHD was used for seven patients whose condition deteriorated markedly due to sepsis or other systemic complications, and their complications were well managed. These different modes of blood purification possibly contribute to the management of complications, as discussed by Nishida et al. [14].

In patients with SAP who developed AKI, the mortality increases to between 20% and 80% [2,3]. In our study, the AKI in all the 26 patients with PMMA-CHD was successfully improved, and hemodialysis therapy was discontinued. ALI/ARDS in SAP also represents a substantial problem, with a reported mortality of up to 50% [6,24]. Gougol et al. [25] reported that the length of ICU stay was protracted in SAP patients with respiratory failure and that the mortality of SAP with MOF was

### Table 3. Profile and data of seven critical cases requiring PMMA-CHD with additional intermittent HDF using a PMMA hemofilter

| Variable                                      | Patient without intermittent HDF | Patient requiring intermittent HDF | P-value |
|-----------------------------------------------|----------------------------------|-----------------------------------|---------|
| Number of patients                            | 19                               | 7                                 | -       |
| Age (yr)                                      | 51.6±16.7                        | 53.3±20.6                         | 0.908   |
| Sex (male:female)                             | 12:7                             | 4:3                               | 0.779   |
| Body mass index (kg/m²)                       | 24.8±3.0                         | 25.7±4.1                          | 0.525   |
| Serum amylase (IU/L)                          | 850±989                          | 1,286±960                         | 0.126   |
| APACHE II score                               | 13.6±7.6                         | 12.1±2.7                          | 0.977   |
| SOFA score                                    | 5.2±2.9                          | 4.0±1.6                           | 0.350   |
| Balthazar CTSI score                          | 6.2±1.5                          | 7.9±1.5                           | 0.018<   |
| Japanese enhanced CT grade                    | 2.4±0.5                          | 2.6±0.5                           | 0.504   |
| KDIGO stage                                   | 2.2±0.8                          | 2.4±0.5                           | 0.593   |
| Lung injury score                             | 3.7±2.6                          | 6.0±1.7                           | 0.031<   |
| Artificial ventilation                        | 9 (47.7)                         | 7 (100)                           | 0.023<   |
| Times of intermittent HDF (number)            |                                  |                                   |         |
| Total days of blood purification              | 3.3±2.1                          | 9.9±4.3                           | <0.01<   |
| Day of ICU care                               | 7.1±4.7                          | 13.9±3.6                          | 0.006<   |
| %Mortality predicted by APACHE II score       | 32.5±36.2                        | 15.6±6.1                          | 0.977   |
| 28-Day survival (%mortality)                  | 19 (0)                           | 7 (0)                             | -       |
| Total hospitalization days                    | 29.6±19.2                        | 31.7±31.6                         | 0.839   |
| Survivor at discharge (%mortality)             | 17 (10.5)                        | 7 (0)                             | 1.000   |

Values are presented as mean±standard deviation unless otherwise indicated.

PMMA-CHD: continuous hemodialysis with a polymethylmethacrylate membrane hemofilter; HDF: hemodiafiltration; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CTSI: computed tomography (CT) severity index; KDIGO: Kidney Disease: Improving Global Outcome; ICU: intensive care unit.

*Statistically significant, P<0.05.
32.4%. In their analysis, patients with MOF were observed to mostly have respiratory failure. In our study, ALI/ARDS did not increase the mortality rates in patients in the hemodialysis group, even in patients who underwent ventilation, as shown in Tables 1 and 2.

A previous study has reported that systemic inflammation was associated with ICU-acquired weakness and indicated that IL-6, TNF-α, or other cytokines could play roles in this pathogenesis [26]. In our study, one patient with ICU-acquired weakness did not show any improvement during treatment with PMMA-CHD. Therefore, it remains unclear whether cytokine regulation with the PMMA hemofilter was effective for ICU-acquired weakness. The cost-effectiveness of blood purification therapy for SAP is another concern. Although the PMMA hemofilter was reported to adsorb the proinflammatory cytokines well, as described above, coagulation in hemofilters during blood purification due to chemostructural changes in membrane surface was found to be a complication [27]. Therefore, a high dose of the anticoagulant nafamostat mesilate was required [28]. Theoretically, CHF was considered
to be effective for adsorbing cytokines [29], and it was reported that the use of CHF was significantly expensive compared with the use of CHD [30]. Based on these findings, we routinely use CHD instead of CHF and hemodiafiltration to maintain longer usage of the PMMA hemofilters in our medical practice. In contrast, we attempted to use additional intermittent PMMA-HDF for deteriorated patients with ARDS/ALI in this study. The combination of PMMA-CHD with intermittent PMMA-HDF showed effectiveness in most of such severer patients, as shown in Table 3; however, the increased costs were noted. The indication of such a combination of blood purification therapies should be considered in future investigations.

This study has several limitations. First, the number of patients was small, and this was a single-center study, thereby limiting the generalization of the study findings. Second, hemofilters using other membrane types that do not absorb cytokines were not used as a control group; therefore, the efficacy of PMMA-CHD could not be clearly determined. Third, we did not measure the serum cytokine levels; therefore, we could not clearly demonstrate the relationship between the performance of cytokine adsorption and the improvement in organ failures. Fourth, considering the retrospective nature of this study, there is definitely a chance that we might have missed some relevant clinical information. Fifth, the problem of cost-effectiveness of blood purification using a PMMA hemofilter was still controversial. These points should be addressed in further studies.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Kiyohiko Kinjoh https://orcid.org/0000-0002-7276-6932
Ryoji Nagamura https://orcid.org/0000-0001-7261-8609
Yutaka Sakuda https://orcid.org/0000-0002-9004-8504
Shoki Yamauchi https://orcid.org/0000-0002-0960-9256
Hideta Takushi https://orcid.org/0000-0001-5020-0201
Tadashi Iraha https://orcid.org/0000-0001-6546-287X
Koji Idomari https://orcid.org/0000-0002-4317-1294

AUTHOR CONTRIBUTIONS

Conceptualization: all authors. Data curation: all authors. Formal analysis: KK. Methodology: KK, YS, KI. Project administration: RN. Visualization: SY. Writing—original draft: KK. Writing—review & editing: KK.

REFERENCES

1. Garg PK, Singh VP. Organ failure due to systemic injury in acute pancreatitis. Gastroenterology 2019;156:2008-23.
2. Zhou J, Li Y, Tang Y, Liu F, Yu S, Zhang L, et al. Effect of acute kidney injury on mortality and hospital stay in patient with severe acute pancreatitis. Nephrology (Carlton) 2015;20:485-91.
3. Nassar TI, Qunibi WY. AKI associated with acute pancreatitis. Clin J Am Soc Nephrol 2019;14:1106-15.
4. Devani K, Charilauop, Radadiya D, Brahmabhett B, Young M, Reddy C. Acute pancreatitis: trends in outcomes and the role of acute kidney injury in mortality: a propensity-matched analysis. Pancreatology 2018;18:870-7.
5. Hu Y, Xiong W, Li C, Cui Y. Continuous blood purification for severe acute pancreatitis: a systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e14873.
6. Kumar P, Gupta P, Rana S. Thoracic complications of pancreatitis. JGH Open 2018;3:71-9.
7. Hirayama Y, Oda S, Wakabayashi K, Sadahiro T, Nakamura M, Watanabe E, et al. Comparison of interleukin-6 removal properties among hemofilters consisting of varying membrane materials and surface areas: an in vitro study. Blood Purif 2011;31:18-25.
8. Yamashita AC, Tomisawa N. Membrane materials for blood purification in critical care. Contrib Nephrol 2010;166:112-8.
9. Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-63.
10. Matsuda K, Moriguchi T, Oda S, Hirasawa H. Efficacy of continuous hemodiafiltration with a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome. Contrib Nephrol 2010;166:83-92.
11. Abe R, Oda S, Shinozaki K, Hirasawa H. Continuous hemodiafiltration using a polymethyl methacrylate membrane hemofilter for severe acute pancreatitis. Contrib Nephrol 2010;166:54-63.
12. Ikeura T, Horibe M, Sanui M, Sasaki M, Kuwagata Y, Nishi K, et al. Validation of the efficacy of the prognostic factor score in the Japanese severity criteria for severe acute pancreatitis: a large multicenter study. United European Gastroenterol J 2017;5:389-97.
13. Yokoe M, Takada T, Mayumi T, Yoshida M, Isaji S, Wada K, et
al. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci 2015;22:405-32.

14. Nishida O, Nakamura T, Kuriyama N, Hara Y, Yumoto M, Shimomura Y, et al. Sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) in the treatment of patients with severe sepsis. Contrib Nephrol 2011;173:172-81.

15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.

16. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.

17. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990;174:331-6.

18. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-84.

19. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.

20. Kobashi S, Maruhashi T, Nakamura T, Hatabayashi E, Kon A. The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center retrospective comparative study. Acute Med Surg 2018;6:60-7.

21. Sharma D, Jakampudi A, Reddy R, Reddy PB,Patil A, Murthy HV, et al. Association of systemic inflammatory and anti-inflammatory responses with adverse outcomes in acute pancreatitis: preliminary results of an ongoing study. Dig Dis Sci 2017;62:3468-78.

22. Cui HX, Xu JY, Li MQ. Efficacy of continuous renal replacement therapy in the treatment of severe acute pancreatitis associated acute respiratory distress syndrome. Eur Rev Med Pharmacol Sci 2014;18:2523-6.

23. Rasch S, Sancak S, Erber J, Wießner J, Schulz D, Huberle C, et al. Influence of extracorporeal cytokine adsorption on hemodynamics in severe acute pancreatitis: results of the matched cohort pancreatitis cytosorbents inflammatory cytokine removal (PACIFIC) study. Artif Organs 2022 Feb 19 [Epub].

24. Zhou MT, Chen CS, Chen BC, Zhang QY, Andersson R. Acute lung injury and ARDS in acute pancreatitis: mechanisms and potential intervention. World J Gastroenterol 2010;16:2094-9.

25. Gougol A, Dugum M, Dudekula A, Greer P, Slivka A, Whitcomb DC, et al. Clinical outcomes of isolated renal failure compared to other forms of organ failure in patients with severe acute pancreatitis. World J Gastroenterol 2017;23:5431-7.

26. Winkelman C, Johnson KD, Gordon N. Associations between muscle-related cytokines and selected patient outcomes in the ICU. Biol Res Nurs 2015;17:125-34.

27. Oshihara W, Fujieda H, Ueno Y. A new poly(methyl methacrylate) membrane dialyzer, NF, with adsorptive and antithrombotic properties. Contrib Nephrol 2017;189:230-6.

28. Yuzawa H, Hirose Y, Kimura T, Shinozaki K, Oguchi M, Morito T, et al. Filter lifetimes of different hemodiafiltration membrane materials in dogs: reevaluation of the optimal anticoagulant dosage. Ren Replace Ther 2021;7:7.

29. Hattori N, Oda S. Cytokine-adsorbing hemofilter: old but new modality for septic acute kidney injury. Ren Replace Ther 2016;2:41.

30. Duriseti P, Idrees N, Aldairem A, Jaber BL, Balakrishnan VS. Cost analysis of two modalities of continuous renal replacement therapy. Hemodial Int 2021;25:173-9.